NOT KNOWN FACTUAL STATEMENTS ABOUT ETOPOSIDE

Procedure with SR18662 significantly minimizes development and proliferation of CRC cells. SR18662 reveals improved efficacy in reducing viability of various CRC mobile traces. Movement cytometry analysis next SR18662 treatment demonstrates an increase in cells captured in possibly S or G2/M phases in the cell cycle and a big rise in the number of